



BARC Global Central Laboratory Announces Participation in the Avoca Diligent Prequalification Platform

Diligent Leverages Avoca Quality Consortium Standards Improve Quality and Reduce Cycle Time in the Prequalification of Technical Providers

(Gent, Belgium, 10/19/16): BARC Global Central Laboratory is pleased to announce its participation in the [Avoca Diligent Prequalification Platform](#). The purpose of this initiative is to increase quality, improve efficiency, reduce risk, and accelerate technical service provider onboarding by centralizing aspects of prequalification activities.

Diligent started by engaging an expert Advisory Board from the Avoca Quality Consortium to develop Industry Standards for Prequalification of technical service providers. These standards were mapped, when possible, to health authority regulations or regulatory guidance. They underwent a rigorous review by The Avoca Group, The Advisory Board, and companies in the industry that deliver these technical services. Upon finalizing the Prequalification Industry Standards, prequalification tools were developed that map back to these standards, including Request for Information (RFI) templates.

The Avoca Group has been inviting [leading technical service providers](#) to complete core and technical RFI templates and centralize them so they are readily available to sponsors (and CROs, if applicable), to speed up the process of prequalifying and onboarding new technical providers. BARC Global Central Laboratory is an early adopter for this transformational initiative and invites sponsors and CROs to contact The Avoca Group at Diligent@theavocagroup.com to request these completed RFIs as needed to accelerate their review and onboarding of BARC for their clinical trials.

“The Avoca Group is pleased that BARC Global Central Laboratory has decided to participate in Diligent,” said Patricia Leuchten, CEO of The Avoca Group. “This is another example of how BARC Global Central Laboratory is taking central lab services to a new dimension by keeping pace with the fast-changing pharmaceutical landscape. Through this collaboration, BARC Global Central Laboratory and Avoca will continue to drive innovation, standardization and streamlining to drug development processes.”

“BARC Global Central Laboratory is proud to be part of this initiative, which will foster easier interactions between sponsors and service organizations, whilst improving quality” said Michel Abiteboul CEO of BARC Global Central Laboratory.

ABOUT BARC GLOBAL CENTRAL LABORATORY

BARC Global Central Laboratory is part of a global lab group, Cerba HealthCare with more than 4200 staff located in its different units. BARC is dedicated to clinical trials and serves large pharmas to biotechs in the different regions of the world. Focusing on innovation and customer

service, BARC is supporting global development of drugs through its network of laboratories in US, Europe, Africa, China, Singapore, Australia and Japan. BARC has been very active in the field of oncology and hemato oncology, working on the front runner drugs globally.

The Company offers a comprehensive range of laboratory services from routine to highly innovative tools including NGS, flow cytometry, and versatile biomarkers in different fields.

For more information about BARC, please visit:

Internet: <http://www.barclab.com>

Twitter: @BARC_CentralLab